Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLS-010
- Development stage
- Preclinical
- Lead developer
- Seelos Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SLS-010 is an orally administered small molecule drug acting as a **histamine H3 receptor antagonist**, under development for the treatment of narcolepsy and other sleep disorders. Its mechanism of action involves blocking the H3 histamine receptor, which is thought to improve wakefulness by modulating histamine-mediated neurotransmission in the central nervous system. SLS-010 was originally developed by Ligand Pharmaceuticals and has been co-developed by Seelos Therapeutics. It is considered a new molecular entity and, as of the latest updates, remains in the preclinical stage of development for narcolepsy[1][3][5].
02
Targets
HRH3 (Histamine Receptor H3)
Beyond the preview
Go deeper on SLS-010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLS-010.